Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05645133 · ClinicalTrials.gov registry record

QPlus Pediatric Reference Interval

A clinical trial, sponsored by HemoSonics.

Terminated
Registry status
93
Enrollment target

NCT05645133: Clinical Trial study, sponsored by HemoSonics.

NCT05645133 is a clinical trial that was terminated before completion, run by HemoSonics. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05645133 was terminated before completion, sponsored by HemoSonics.

TERMINATED
Registry status
93 participants
Enrollment target

Study Summary

Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.

Primary Outcome

Reference range interval determined in this study will serve as the reference for CT results in this particular population

Interventions

  • DEVICE Diagnostic Test

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2023-02-27
Est. Completion 2023-06-10
HemoSonics

24 total trials

Why NCT05645133 stopped before completion

NCT05645133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Diagnostic Test is the first listed.

NCT05645133 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05645133 about?

NCT05645133 is a clinical study titled "QPlus Pediatric Reference Interval". Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.

What is the current status of trial NCT05645133?

This trial is currently terminated. The enrollment target is 93 participants. The study started on 2023-02-27. Estimated completion is 2023-06-10.

What interventions are being tested in trial NCT05645133?

The interventions under investigation include: Diagnostic Test (DEVICE).

Who is sponsoring clinical trial NCT05645133?

This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05645133, the US trial registry maintained by the National Library of Medicine. NCT05645133 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.